Assessment of Rifaximin and Rifampicin Resistance Across Clostridioides Difficile Ribotypes: A Systematic Review and Meta-Analysis
Letters in Applied Microbiology · 2026
DOI: 10.1093/lambio/ovag018 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Letters in Applied Microbiology, 2026. Verfasst von Nasser Alkhushaym und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Care Department, Royal Commission Health Services Program, Jubail 31961, Saudi Arabia. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Clostridioides difficile, Clostridium Infections, Drug Resistance, Bacterial.
Abstract (Originalsprache)
Clostridioides difficile is an opportunistic pathogen of the gastrointestinal tract that can cause illnesses ranging from diarrhea to pseudomembranous colitis. Recurrent Clostridioides difficile infection remains a major clinical challenge, with substantial relapse rates after standard antibiotic therapy. Emerging evidence suggests that rifaximin can be used after the conventional therapy to reduce risk of the recurrence. However, rifaximin resistance in Clostridioides difficile remains the primary concern. The aim of this systematic review and meta-analysis is to estimate the risk of rifaximin resistance in Clostridioides difficile infection and among different ribotypes. The search included PubMed, Scopus, Web of Science, and Cochrane Library for studies reporting rifaximin resistance in Clostridioides difficile isolates. After systematically screening 731 records from all databases and excluding 664 studies, a total of 67 studies were included in the meta-analysis. The findings of the meta-analaysis indicated a resistance rate of 15.1% (95%CI,12.0%–18.9%) for rifaximin and/or rifampicin and 12.8% (95%CI,8.8%–18.2%) for rifaximin alone. Ribotype-specific analysis revealed high rifaximin resistance in RT017(72.3%), RT027(47.0%), and RT018(20.9%), while RT012, RT002, RT112, and RT014/020 demonstrated low resistance. The study finding indicate that rifaximin/rifamycin resistance in Clostridioides difficile is concerning and not randomly distributed but is more frequently associated with certain ribotypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Care Department, Royal Commission Health Services Program, Jubail 31961, Saudi Arabia.
- Department of Pharmacy Practice, College of Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.
- Emergency Department, Royal Commission Health Services Program, Jubail 31961, Saudi Arabia.
- Pathology and Laboratory Medicine Department, Security Forces Hospital, Riyadh 11564, Saudi Arabia.
- Pharmacy Practices Department, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
ORCID-Profile: Nasser Alkhushaym, Abdullah Alhifany
Zitieren
APA
Alkhushaym, N., Alabbad, R., Alqarni, Y. S., Almalki, N., Alanazi, R. K., & Alhifany, A. (2026). Assessment of Rifaximin and Rifampicin Resistance Across Clostridioides Difficile Ribotypes: A Systematic Review and Meta-Analysis. Letters in Applied Microbiology. https://doi.org/10.1093/lambio/ovag018
Vancouver
Alkhushaym N, Alabbad R, Alqarni YS, Almalki N, Alanazi RK, Alhifany A. Assessment of Rifaximin and Rifampicin Resistance Across Clostridioides Difficile Ribotypes: A Systematic Review and Meta-Analysis. Letters in Applied Microbiology. 2026. doi:10.1093/lambio/ovag018
BibTeX
@article{Alkhushaym2026,
author = {Alkhushaym, Nasser and Alabbad, Rawan and Alqarni, Yousef Saeed and Almalki, Naif and Alanazi, Reem Khader and Alhifany, Abdullah},
title = {Assessment of Rifaximin and Rifampicin Resistance Across Clostridioides Difficile Ribotypes: A Systematic Review and Meta-Analysis},
journal = {Letters in Applied Microbiology},
year = {2026},
doi = {10.1093/lambio/ovag018}
}
EUVIMED